The present invention relates to a capsule comprising a faecal composition for oral administration wherein the faecal composition comprises a stool fraction and a diluent, wherein the stool fraction comprises one or more non-pathogenic microorganisms, and wherein the diluent comprises a cryoprotectant resulting in a final concentration of cryoprotectant in the faecal composition below 8% (v/v) cryoprotectant.

The present invention provides a method of administering doses of the BTK inhibitor, (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide or a pharmaceutically acceptable salt thereof for use in treating conditions such as cancer and autoimmune diseases.

Disclosed herein are compositions and methods for the treatment and/or detection of diseases such as, but not limited to Lyme disease, Lyme disease-related disorders including post-treatment Lyme disease syndrome (PTLDS), chronic Lyme disease (CLD) and/or inflammation.

Disclosed herein are compositions and methods for ovulation induction in females in need thereof. Current methods for inducing ovulation have unpleasant side effects and are expensive. The disclosed compositions and methods are safe, efficacious, and inexpensive. An exemplary method of inducing ovulation includes steps of monitoring ovarian follicle development and size during the follicular phase of the menstrual cycle; and administering to the subject a pharmaceutical composition including progesterone or ioidentical progesterone in an amount effective to increase the plasma concentration of progesterone to between about 0.1 ng/ml to about 1 ng/ml when the follicle reaches a size of at least 15 mm.

The present disclosure relates to engineered microbial cells that have been engineered to include a uricase, a uric acid transporter, or both a uricase and a uric acid transporter. The engineered microbial cells of the present disclosure are useful in degrading uric acid inside the engineered microbial cell. The engineered microbial cells of the present disclosure are useful in methods of treating hyperuricemia. The engineered microbial cells of the present disclosure are also useful in methods of treating gout, and in particular chronic refractory gout.

The present disclosure is generally directed to a composition comprising a minicell and an active agent and to a bacterial minicell comprising an active agent. The compositions are suitable for improving animal health, increasing live stock production, or preventing animal-to-human transmission from both domestic animals and wildlife populations. Disclosed herein are methods of preparing a minicell encapsulating an active agent, delivering an active agent to a subject, and producing an animal feed and/or an animal vaccination for improving animal health and welfare.

Disclosed herein are methods of treating lymphedema that include administering a clinically effective amount of deupirfenidone.

A method of reducing systemic chronic inflammation in a subject by administering a composition capable of reducing the expression level of inflammatory biomarkers.

Compositions promote restful sleep and/or to a feeling of restful sleep. Specifically, the compositions of the present invention comprise a combination of hops extract, magnolia bark extract, melatonin, magnesium, rhodiola extract, L-theanine, vitamin B6, and spearmint extract and/or green tea extract to promote restful sleep and/or a feeling of restful sleep in an individual or animal. Methods of making and using the same are further provided.

The present disclosure provides a compositions and methods of inhibiting O.sup.6-methylguanine DNA methyltransferase in human tumor cells by providing an effective amount of an agent that directly or indirectly inhibits the O.sup.6-methylguanine DNA methyltransferase in a pharmaceutically acceptable carrier, wherein the amount is effective to potentiate an anti-tumor activity of one or more alkylating agents, platinum drugs, or antimetabolites, wherein tumor cells are triggered into programmed cell death.